Latest news with #MatthewHarris
CBS News
22-05-2025
- CBS News
Colorado mountain sheriff says agency has made strides in the right direction for community policing
Deputies for some of Colorado's mountain communities found out in April they wouldn't be charged after using deadly force earlier this year. Their boss believes the ruling in the favor of his deputies is a sign of his agency's long-term steps in the right direction of community policing. This comes after one of his deputies did ultimately face consequences for his actions. Deputies ended up firing multiple times on Christine Lewis before killing her back in March. This happened, according to reports, after a felony traffic stop, where Lewis, 36, pointed a gun at deputies and officers for a combined 17 minutes. After utilizing less-lethal options, including beanbag rounds, deputies opened fire on her. In the April report from Colorado's 5th Judicial District, District Attorney Heidi McCollum clears the law enforcement officers of any wrongdoing, and explained that deputies exercised, "great restraint in not firing lethal rounds at her sooner than they did." Clear Creek County Sheriff Matthew Harris. CBS Clear Creek County Sheriff Matthew Harris told CBS Colorado this is exactly the kind of change that's come from training, culture changes and personal changes at CCCSO. All these changes have come in the wake of the 2022 shooting and killing of Christian Glass by a deputy. "Every single one (of our employees) will think about the Christian Glass case for a long time," Harris explained. "As I've said before, what happened to Christian Glass was a tragedy, and it was an organizational failure." Harris said he sees the operation to subdue Lewis as unfortunate, but one where his deputies did what they were trained to do, and worked to protect the public in a lawful way. He believes, when the DA references "restraint," she's talking about his employees' efforts to create an ending without taking a life. "It means doing everything possible to ensure that the outcome ends as safe to the community, and to the individual, and to the officers as possible," Harris said. In dashboard camera recorded from an Idaho Springs Police Department cruiser, Lewis swings her arm, pointing a handgun at deputies and officers multiple times while law enforcement takes cover behind vehicles. Eventually, Lewis walked closer and closer to the side of the vehicle many officers were using for cover, giving her a better line of sight and clearer shot, and that's when a captain with the CCCSO fired his duty rifle at Lewis, alongside other officers and deputies, and Lewis fell to the ground. Law enforcement advances on her, and Lewis rolls from her side toward officers and again points her handgun directly at officers, who are now only a few feet away. Law enforcement officers open fire once again, killing Lewis. Clear Creek also had it's Community Crisis and Health Assistance Team (CCHAT) on standby. It's a program put in place after the death of Glass to help end conflicts like this without a loss of life. But because it was an armed and dangerous criminal situation regarding a felony warrant, volunteers were not safely able to make it on scene to negotiate with Lewis. Harris said, while there's many different aspects of the office that have been corrected, it's not a time to become complacent. "When you are happy with your success, that will lead to your failure," Harris said. "So this has to be a department where we look for continuous improvements. We we have to celebrate our victories. We don't spike the football. We continue to get better, and my mantra has been, 'We get a little bit better every day.'" As for backsliding, Harris said he can make a promise that CCCSO will not fall back into it's old ways, where the community cannot trust them with their own safety. "If (our) people make critical mistakes, they will not be here any longer," Harris said. "People make minor mistakes, of course, and we correct, we fix them, and we go back to training, and we make them better. But you come here and you make critical mistake, we can't have you."
The Irish Sun
13-05-2025
- Health
- The Irish Sun
Fat jabs slash risk of silent killer which affects thousands of Brits a year by HALF, incredible study finds
FAT jabs are being lined up as a cancer-beating super weapon as research shows they halve the risk of developing the disease. Users had a lower danger than those who had slimming surgery — even if they did not lose as much weight, a study found. Advertisement 1 Fat jabs could become a super weapon in the fight against cancer Credit: Getty It suggests injections like Ozempic, Wegovy and Mounjaro have anti-cancer effects on top of reducing the risk by burning fat. Cancer experts now want to test tens of thousands of people in a crucial clinical trial.. They believe the effects on inflammation, hormones and chemicals in the blood might offer added protection on top of the benefits of weight loss. Dr Matthew Harris, of the Manchester Cancer Research Centre, said: 'Injectable weight loss medications give a genuinely promising possible option for cancer prevention in the future.' Advertisement READ MORE ON FAT JABS Experts believe their effects on inflammation, hormones and chemicals in the blood might add extra protection on top of the benefits of weight loss. A study compared 3,200 patients who lost weight with GLP-1 injections with 3,200 who had surgery. Follow-up tests showed the cancer rate in surgical patients compared with jab patients. Study author Dr Yael Wolff Sagy, of Clalit Health Services in Israel, said: 'When we took into account the differences in weight reduction, we found the jabs were 41 per cent more effective at preventing cancer. Advertisement Most read in Health 'This indicates there is an additional mechanism beyond simple weight loss. We believe this effect may come from reducing inflammation. 'This is potentially very exciting news for patients at high risk of obesity-related cancer and possibly other cancers.' Professor Mark Lawler, from Queen's University Belfast, was not part of the study but commented: 'We already know that bariatric surgery cuts obesity-related cancer risk by about a third and these data suggest that GLP-1s may cut that risk by nearly 50 per cent. 'This work could herald a whole new era of preventative cancer medicine.' Advertisement Dr Harris and dozens of international researchers told the European Congress on Obesity that a trial pitting the jabs against cancer should be a priority. It could involve comparing disease rates among tens of thousands of patients with and without the drugs over a number of years. Obesity is the second most common cause of cancer in the UK, behind smoking, and around a third of Brits are severely overweight. Dr Harris added: 'There is going to be a massive increase in obesity related cancers so if we're able to prevent them it could be a really significant public health intervention.' Advertisement Experts hope the trial could be under way within three to five years. Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. Julia Hartley-Brewer slams government plan for NHS to offer free 'fat jabs' to tackle obesity crisis
Telegraph
12-05-2025
- Entertainment
- Telegraph
William Sitwell reviews Harry's, Camber: ‘A menu that matches the spirit of the place'
Of course, I was invigorated by the sight of the sea, what seemed a vast and empty stretch of water, and an equal expanse of beach, with no one in sight but a couple of dog walkers. And there wasn't a cloud in the sky. Fortunately the car parks were also empty because, given they are also enormous, it suggests this place becomes less of a picnic mid-summer; a sort of Saturday night peak-time ITV1 grockle-fest. But my spirits soared further when I entered The Gallivant, just opposite one of those car parks by Camber Sands, near Rye, in East Sussex. Because it is nothing less than a visionary's accomplishment. What could be a single-storey motel by a busy road is a stylish retreat so well designed and propped that you want to take every idea, every cushion, book, chessboard and sconce home. Along with the staff, who usher you in offering beach towels, boots and water bottles. And now this little paradise has a great chef in its midst. The restaurant is called Harry's, named not after the chef, Matthew Harris, but owner Harry Cragoe. Harris is one half of a culinary sibling duo, his brother being Henry, of celebrated Bouchon Racine fame. And while Henry had classic chef itchy feet syndrome, also known as restaurateuritis, Matthew fetched up at London's Bibendum about a hundred years ago and stayed there until he felt it was time to cook in a nice place by the sea. Where he reigns over breakfast too, which I liked almost more than dinner; so cute is the array of granola, cured hams, cheeses and a Bloody Mary 'recovery station'. The menu is sort of French by way of Kent; French words like 'terrine de campagne', 'courchamps', 'montpellier' and 'remoulade' being in the mix with 'Salt Marsh Barnsley chop' and 'wild garlic'. And very gently reassuring it is too, a menu, indeed, that matches the spirit of the place: calm and restorative. My hot date Nima ('I've not been called that since 1972'), a beloved family friend, enjoyed her terrine, the rustic kind embedded with pistachios, though, she said, it wasn't groundbreaking. And I, similarly, nestled into a familiar Harris brothers starter of eel with celeriac and egg – gentle flavours, the sensible foundations of a house rather than its grand façade. Next I ate a bit of sheep like the ones I'd spotted grazing as I travelled from the station, the Barnsley chop, slow-braised and glistening, sweet but robust. It came with half a baby gem, fresh from the griddle. I never quite know how chefs do that with lettuce, try it at home and it turns to mush, a bit like my attempts at taramasalata which taste like cat food. Nima's main was veal, another decent plate, tender meat, charred at the edges and under a verdant, generous pour of montpellier butter. We shared buttery spinach and fries, all on point and elegantly served on handsome plates painted with an 'H', which I suppose, stops you pinching them, unless your name is Harry or Helga or Harvinder. Vanilla ice cream for pud came with room temperature chocolate sauce, which I think should be hot. But then it's a bit like a reverse of the braised lettuce thing: I can make hot chocolate sauce at home, but no restaurant can, ever. In the choppy waters of modern hospitality, as vessels smash against the rocks, The Gallivant sails a smooth and calm path – now resolutely, with a chef on board who doesn't want to change the world but instead reliably helps the boat to keep on chugging along very nicely.
Daily Mirror
11-05-2025
- Health
- Daily Mirror
Weight loss injections may have an anti-cancer effect ‘beyond weight loss'
A team based at the University of Manchester, funded by Cancer Research UK, are designing a clinical trial involving tens of thousands of patients, which they hope to get underway within 'three to five years' Weight loss jabs could cut cancer risk by almost half and be given to people who are not obese, scientists say. Landmark research appears to confirm the appetite-suppressing jabs which mimic a hormone that makes us feel full can also reduce risk from over a dozen obesity-related cancers. Experts suspect they are having an anti- cancer effect on top of the weight loss by also reducing inflammation in the body. Half of us will get cancer in our lifetimes and researchers presenting the findings at the European Congress on Obesity in Malaga, Spain, say the jabs should now be considered to prevent this for people at risk. The weekly injections are currently prescribed for weight loss and Type 2 diabetes curb hunger pangs by mimicking the glucagon-like peptide 1 (GLP-1 hormone which regulates feelings of fullness. Study author Dr Yael Wolff Sagy, of Clalit Health Services, Tel-Aviv, Israel, said: "This is potentially very exciting news for patients who are at high risk of obesity-related cancer, and possibly even other cancers. This indicates there is an additional mechanism with the jabs beyond simple weight loss. We believe this effect may come from the inflammation-reducing quality of GLP-1s. But of course, this type of study cannot say for sure that that's the mechanism. "I believe there could be a future where people who are not obese, but have other risk factors for cancer, could be prescribed GLP-1s to help prevent it.' A team based at the University of Manchester, funded by Cancer Research UK, are designing a clinical trial involving tens of thousands of patients, which they hope to get underway within 'three to five years'. Unveiling the trial at Europe's major obesity conference, a team of international experts issued a statement calling for weight-loss drugs such as Wegovy and Mounjaro to be trialled for cancer prevention. The consensus statement was backed by 54 specialists from 12 countries, including 25 from the UK. Lead author Dr Matthew Harris, of the Manchester Cancer Research Centre, said: 'Rates of obesity have been rising quite substantially across the world for the past 30 years. We haven't seen any country, particularly in the West, able to curb that going to be this massive increase in obesity related cancers. If we're able to reverse obesity and prevent those cancers from happening, it could be a really significant public health intervention. 'Prevention is really important in cancer, especially now we have a weapon to potentially reduce one of the major risk factors, in new drugs do provide genuinely fantastic weight loss, and may provide an intervention that could be delivered on a population-scale, where we have not been able to achieve this before.' The Israeli researchers analysed electronic health record data on 6,356 adults treated for obesity and type 2 diabetes. Half received bariatric surgery such as gastric band surgery, and half received first generation weight loss jabs liraglutide, exenatide, or dulaglutide. Over a typical follow-up of 7.5 years, 298 patients were diagnosed with obesity-related cancer, and a similar rate in each group. Once the additional weight loss from surgery was factored in the study found jabs were 41% better at preventing weight-related cancers. A previous systematic review found the surgery cut the chances of patients developing cancer by 38%. Combining the data it suggests that GLP-1s alone could cut cancer risk by almost half. Professor Mark Lawler, an international cancer researcher expert from Queen's University Belfast, who was not involved in the research, said: "These results are very exciting - we already know that bariatric surgery cuts obesity-related cancer risk by about a third; these data suggest that target GLP-1s may cut that risk by nearly 50% - an approach that would be transformational in preventing obesity-related cancer. 'Biologically, this makes sense, as targeting GLP-1 dampens down inflammation, one of the hallmarks of cancer. While further work is required on how it works, these data raise the intriguing possibility that a GLP-1 agonist jab could prevent multiple cancers in the general population. This work could herald a whole new era of preventative cancer medicine " Study co-author Professor Dror Dicker cautioned that it was difficult to quantify the exact effect of GLP-1s on cancer prevention but they appeared to have a more powerful mechanism than bariatric surgery - which trials have shown cuts the risk of obesity-related cancers by between 30% and 42%. Jason Halford, former president of the European Association for the Study of Obesity said the breakthrough could herald a 'new dawn' in cancer prevention. He said: 'I suspect oncologists will be interested in prescribing anti-obesity drugs. This has the potential to reduce the burden on oncology services in the NHS.' Dr Yael Wolff Sagy added: "We do not yet fully understand how GLP-1s work, but this study adds to the growing evidence showing that weight loss alone cannot completely account for the metabolic, anti-cancer, and many other benefits that these medications provide. 'When we compared the risk reduction in patients who had a surgery versus those who used weight-loss medication, we saw it remained the same - even though the surgery patients lost a lot more weight. When we took into account the differences in weight reduction, we found the jabs were 41% more effective at preventing cancer." She added: "These drugs could be useful for a wide range of conditions. We would like to study other inflammation-related conditions, such as blood clots, to see if this effect is reproduced. The issue is that demand for these drugs is already through the roof. "[Pharmaceutical companies] will need to figure out a way of making them cheaper, because right now the new generation medications are quite expensive, and in terms of public health health systems, I'm not sure they are considered cost-effective, despite all their amazing advantages."
Scottish Sun
11-05-2025
- Health
- Scottish Sun
Fat jabs slash risk of silent killer which affects thousands of Brits a year by HALF, incredible study finds
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FAT jabs are being lined up as a cancer-beating super weapon as research shows they halve the risk of developing the disease. Users had a lower danger than those who had slimming surgery — even if they did not lose as much weight, a study found. Sign up for Scottish Sun newsletter Sign up 1 Fat jabs could become a super weapon in the fight against cancer Credit: Getty Cancer experts now want to test tens of thousands of people in a crucial clinical trial.. They believe the effects on inflammation, hormones and chemicals in the blood might offer added protection on top of the benefits of weight loss. Dr Matthew Harris, of the Manchester Cancer Research Centre, said: 'Injectable weight loss medications give a genuinely promising possible option for cancer prevention in the future.' The study compared 3,200 patients who lost weight with GLP-1 injections with 3,200 who had surgery. READ MORE ON FAT JABS DOUBLE WHAMMY Fat jabs like Ozempic slash boozing by two-thirds Follow-up tests showed the cancer rate in surgical patients compared with jab patients. Study author Dr Yael Wolff Sagy, of Clalit Health Services in Israel, said: 'When we took into account the differences in weight reduction, we found the jabs were 41 per cent more effective at preventing cancer. 'This indicates there is an additional mechanism beyond simple weight loss. We believe this effect may come from reducing inflammation. 'This is potentially very exciting news for patients at high risk of obesity-related cancer and possibly other cancers.' Dr Harris and dozens of international researchers told the European Congress on Obesity that a trial pitting the jabs against cancer should be a priority. Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
